CDRE · Cadre Holdings, Inc.

The thesis

Cadre Holdings' third quarter showed real growth, with sales up 30%, organic growth back to 10% and a first $100 million buyback. Thin guidance and a shrinking backlog keep the case finely balanced. The fourth-quarter report, expected around early March 2027, decides whether that growth carries into 2027 or was partly pulled forward.

Cadre makes safety and survivability gear: body armor, duty gear, bomb-disposal suits and nuclear safety products. It reported on 4 November 2026. Net sales were $202.9 million, against $155.9 million a year earlier. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, as adjusted by the company) was $41.1 million at a 20.2% margin, up from 19.1%.

Since the previous note, the only new fact is another analyst raise. Roth MKM kept its Buy rating and raised its price target on 10 November 2026, according to company news. That follows JP Morgan's move to $40 from $35 on 7 November 2026. Neither changes the business numbers. The next real test is the fourth-quarter report.

The narrative is maturing: investors know the acquisition-led growth story well, and the shares closed at $33.77 on 10 November 2026, 26.0% below their 52-week high of $45.62. The two target raises after the 4 November 2026 report have brought some attention back. The shares closed 0.1% lower than three months earlier.

Bullish and bearish views on Cadre Holdings, Inc.

The bull case on Cadre Holdings, Inc. (CDRE), in brief: Organic growth has turned up. The bear case: Part of the beat was timing.

Bull case

• Organic growth has turned up. Earnings Whispers reported on 5 November 2026 that organic growth excluding distribution reached 10% in the third quarter, up from 5% in the second quarter and negative in the first.
• Margins are expanding on higher volume. The adjusted EBITDA margin rose 110 basis points to 20.2% in the third quarter, and gross margin rose to 43.4% from 42.7%, according to the company's 4 November 2026 release.
• First buyback adds a buyer. On 4 November 2026 the board authorized up to $100 million of share repurchases, the company's first program. The quarterly dividend of $0.10 per share is payable on 13 November 2026.
• Second guidance raise in a row. On 4 November 2026 the company set 2026 net sales at $756–769 million, up from $749–769 million, and adjusted EBITDA at $140–144 million.
• Analysts are raising targets again. JP Morgan raised its target to $40 from $35 on 7 November 2026, reversing its 13 October 2026 cut, and Roth MKM raised its target on 10 November 2026. A 7 November 2026 Defense World item, citing MarketBeat data, put the consensus target at $43.33 from one Strong Buy, five Buy and two Hold ratings.

Bear case

• Part of the beat was timing. Earnings Whispers estimated on 5 November 2026 that about $10 million of next-generation bomb-suit shipments were pulled into the third quarter from later in the year.
• Only the low end of guidance rose. The top of the range stayed at $769 million in sales and $144 million in adjusted EBITDA. Earnings Whispers said the guidance implies fourth-quarter sales of about $197 million, below the third quarter, and that full-year organic growth guidance narrowed to 3–4% from 3–5%.
• Backlog is shrinking from its peak. Total backlog fell about $29 million from the second quarter, after a record $355 million in the first quarter, according to Earnings Whispers on 5 November 2026.
• Debt has risen with acquisitions. Net debt reached $305.6 million at 30 September 2026, up $121.2 million since year-end 2025, and cash fell to $63.9 million (company release, 4 November 2026). Funding the buyback and further deals from that position leaves less room.
• The chief executive sold near current prices. Chairman and CEO Warren Kanders sold 100,000 shares on 24 August 2026 at an average $33.36, leaving him with 9,517,039 shares, according to a 7 November 2026 Defense World item citing SEC filings.

Price setup

The shares closed at $30.84 on 4 November 2026, before the after-market report, and at $32.27 on 5 November 2026, the session after it. They rose to $34.18 on 9 November 2026 and closed at $33.77 on 10 November 2026. The 52-week high is $45.62, so the post-report rally has recovered only part of the earlier decline.

A 7 November 2026 Defense World item put the 200-day moving average at about $32.13 and the 50-day moving average at $27.90. The shares now trade above both, after crossing the 200-day average that week. The 14-day relative strength index (a momentum gauge where readings above 70 are usually called overbought) stood at 78.3 on 10 November 2026.

Crowding is visible in momentum, not in news flow. The overbought reading and the wide gap above the 50-day average show a fast run in a few sessions. The next earnings date is about four months away, and there has been no new share issuance since the report. Insiders held 30.10% of the shares, according to the same 7 November 2026 item.

Catalysts, next 30 days

• 13 November 2026: payment of the $0.10 quarterly dividend to holders of record on 30 October 2026. This is routine and does not test the growth case.
• ~5 March 2027, est.: fourth-quarter and full-year 2026 results, with first 2027 guidance. This report shows whether fourth-quarter sales land near the implied $197 million, whether backlog stabilises, and how much stock was repurchased. The case turns on it.

No company-scheduled event inside the next 30 days tests the case. Until the March report, the shares are likely to trade on analyst revisions and group moves.

What would change the view

The case breaks if the third quarter proves to be a timing peak. That would show up as fourth-quarter sales well short of the roughly $197 million implied by guidance, or a second straight sequential backlog decline at the early-March 2027 report. Net debt rising further above $305.6 million with little stock repurchased would also weaken it, because it would mean acquisitions are crowding out the buyback.

On price, a daily close below $30.84, the 4 November 2026 pre-report close, would erase the post-report gain and put the shares back under the roughly $32 200-day average. The case would firm if 2027 guidance implied organic growth above the 3–4% 2026 range and backlog moved back toward the $355 million first-quarter record.

What it trades with

Cadre sits in the defense and aerospace group alongside ULBI, KRMN and SARO, and that group has drawn more attention since early November. Cadre's customers are mostly law enforcement, first responders and nuclear safety buyers rather than prime defense contractors. That makes its shares less tied to defense-budget news than its peers.

About 8% of revenue comes from consumer holsters, according to Earnings Whispers, and that line moves with political events. A broad cooling in the defense group would weigh on the shares in the short run. It would not change the fourth-quarter test, which rests on Cadre's own orders and backlog.